Characteristics of the patients before the first TFR attempt
| Characteristics . | Values . |
|---|---|
| Demography | |
| Age, median (range), y, NS | 48.5 (18.9-80.2) |
| Sex ratio (M/F) | 0.49 |
| Disease characteristics | |
| Sokal score %, low/intermediate/high, NS | 58/26/16 |
| CML duration before TFR1, median (range), y, NS | 7.6 (3.3-28.5) |
| Therapy before TFR1 | |
| TKI duration, median (range), y, NS | 8.4 (3-18.8) |
| Ongoing TKI | |
| Imatinib, n (%) | 76 (61) |
| Including imatinib post-IFN, n | 25 |
| 2G TKI postimatinib, n (%) | 38 (28) |
| Including 2G TKI postimatinib and IFN, n | 12 |
| 2G TKI first line, n (%) | 14 (11) |
| Including 2G TKI first line plus IFN, n | 1 |
| Previous IFN (total) | 38 (29.7) |
| Response before TFR1 | |
| MR4, % | 100 |
| MR4 duration, median (range), y | 4 (1.4-12.9) |
| Stable MR4, % | 81 |
| MR4.5, % | 85 |
| MR4.5 duration, median (range), y | 2.9 (0.5-12.8) |
| Stable MR4.5, % | 67.2 |
| Characteristics . | Values . |
|---|---|
| Demography | |
| Age, median (range), y, NS | 48.5 (18.9-80.2) |
| Sex ratio (M/F) | 0.49 |
| Disease characteristics | |
| Sokal score %, low/intermediate/high, NS | 58/26/16 |
| CML duration before TFR1, median (range), y, NS | 7.6 (3.3-28.5) |
| Therapy before TFR1 | |
| TKI duration, median (range), y, NS | 8.4 (3-18.8) |
| Ongoing TKI | |
| Imatinib, n (%) | 76 (61) |
| Including imatinib post-IFN, n | 25 |
| 2G TKI postimatinib, n (%) | 38 (28) |
| Including 2G TKI postimatinib and IFN, n | 12 |
| 2G TKI first line, n (%) | 14 (11) |
| Including 2G TKI first line plus IFN, n | 1 |
| Previous IFN (total) | 38 (29.7) |
| Response before TFR1 | |
| MR4, % | 100 |
| MR4 duration, median (range), y | 4 (1.4-12.9) |
| Stable MR4, % | 81 |
| MR4.5, % | 85 |
| MR4.5 duration, median (range), y | 2.9 (0.5-12.8) |
| Stable MR4.5, % | 67.2 |
F, female; IFN, interferon; M, male; MR4, BCR-ABL1IS ≤0.01%; MR4.5, BCR-ABL1IS ≤0.0032%; NS, values not significant.